Lindsay Fischer

Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.

Aspirating prior to flushing allows nurses to check implanted vascular access devices for abnormalities.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

An oncology nurse initiative increased the rate of end-of-life discussions in patients with advanced cancer.

Olanzapine demonstrated efficacy in improving appetite and weight gain in patients receiving cytotoxic chemotherapies.

Kristin Daly, MSN, ANP-BC, AOCNP, discusses pathogenic variant testing and what it means for oncology nurses.

A doublet regimen of enfortumab vedotin and pembrolizumab has received accelerated approval for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy.

La-Urshular Brock, MSN, FNP-BC, CNM, discusses how a better understanding of HER2-low status may necessitate more testing for certain patients with breast cancer.

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

Retifanlimab has received accelerated approved for patients with metastatic or recurrent, locally advanced merkel cell carcinoma.

The International Pediatric Fever and Neutropenia Guideline Panel have reconvened and released a 2023 clinical practice guideline update.

Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.

In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.

Patricia Jakel, RN, MN, AOCN discusses adverse event management in the age of new breast cancer treatments.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.

Elranatamab, an investigational BCMA/CD3-targeted bispecific antibody, has received priority review status for patients with relapsed or refractory multiple myeloma.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.

The FDA has granted avasopasem a priority review for severe oral mucositis in patients with head and neck cancer who are receiving radiotherapy.

Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.